You have permission to edit this article. Edit Close Facebook Twitter YouTube Instagram ...

The stock of small-cap biotech Jaguar Health ... will develop oral mucositis of grade 3 or 4 which will put them in the hospital for parenteral nutrition and iv hydration. The gel has a mechanical ...

Jaguar's president and CEO. "Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a gel with a mechanical action indicated for the ...

The stock of small-cap biotech Jaguar Health Inc. rose 3% on Wednesday, after the company launched its gelclair treatment for oral mucositis, a common side effect suffered by head and neck cancer ...

SAN FRANCISCO - Jaguar Health, Inc. (NASDAQ:JAGX) has announced the U.S. commercial launch of Gelclair, an FDA-approved treatment for oral mucositis, a common and painful side effect of cancer therapy ...

Jaguar's president and CEO. "Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a gel with a mechanical action indicated for the ...

Jaguar's president and CEO. "Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a gel with a mechanical action indicated for the ...

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account. We offer one free story view per month. If you ...